Why authorisation does not mean availability

The MHRA authorised orforglipron on 10 August 2026, making the UK the first country in Europe to license it. That decision confirms the medicine is safe, effective and of sufficient quality to be sold here. It does not put a single tablet into a single pharmacy.

Between authorisation and availability sit several separate steps, each with its own timetable: the manufacturer decides when to launch in a given market and at what price; supply chains are established with wholesalers; and, for NHS supply, a completely separate value assessment has to conclude. A medicine can be licensed for months before it reaches patients, and the order in which countries get it is a commercial decision rather than a regulatory one.

As of today, orforglipron cannot be obtained in the UK by any route — NHS or private. No prescriber here can supply it.

The NHS position

The MHRA was explicit in its announcement: orforglipron is not currently available on the NHS.

NHS availability is decided by NICE, not the MHRA. NICE assesses whether a medicine represents good value for the health service — a different question from whether it works. That appraisal is already under way under reference ID6516, and guidance is currently expected on 18 November 2026.

Two caveats are worth holding on to. First, NICE timetables move; the date is an expectation, not a commitment. Second, and more importantly, a positive NICE decision would not mean immediate access for everyone. When tirzepatide was recommended for weight management, NHS rollout was phased over several years and prioritised by clinical need, starting with those at highest risk. There is no reason to expect a different approach here.

There is also a separate question nobody has answered yet: NICE’s current appraisal covers the overweight and obesity indication. Orforglipron was also authorised for type 2 diabetes, and how that indication will be handled for NHS use has not been set out.

What will determine the private cost

When orforglipron does launch privately, several factors will shape what patients pay. Understanding them is more useful than any current guess at a headline figure.

The dose you end up on

This is the big one, and it is the factor most consistently missing from the coverage. Orforglipron is not one product at one price. There are six strengths — 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg — and higher strengths generally cost more.

Because treatment must spend a minimum of one month at each level, reaching the highest dose takes at least five months, and the monthly cost changes as you go. Anyone thinking about affordability should be thinking about the cost of the whole escalation, not the price of the first month.

The table shows the minimum schedule. In practice many people move up more slowly, and some settle at a middle dose rather than the maximum — which costs less. The right dose is the one that works and is tolerated, not automatically the highest.

Whether it is a long-term treatment

Evidence across the GLP-1 class consistently shows that weight tends to return when treatment stops. Orforglipron is licensed for weight loss and weight maintenance, and the main weight-management trial ran for 72 weeks. Anyone budgeting on the basis of a three-month course is likely to be budgeting for the wrong thing.

Competition

Orforglipron enters a UK market that already contains several licensed weight-management medicines, including one other oral GLP-1 authorised only two months earlier. Competition on price is likelier here than in categories with a single product — but a genuinely differentiated product, taken as a daily tablet with no fasting routine, may not be priced to undercut.

What the medicine costs is not the whole cost

Private treatment involves a clinical assessment, prescriber time, dispensing and ongoing review. Any figure quoted for a medicine alone is not the figure a patient pays.

The United States figures, and why they do not transfer

Orforglipron was approved in the United States before the UK, and self-pay prices there have been published. Those figures are widely quoted in UK articles, usually converted into pounds.

Treat that conversion as meaningless. US and UK pricing for the same medicine routinely differ by large multiples in both directions, because the two markets are structured completely differently — the US has insurance intermediaries, rebates and manufacturer savings cards; the UK has NHS pricing agreements alongside a private market with its own dynamics. A US self-pay price converted at today’s exchange rate tells you almost nothing about what a UK pharmacy will charge.

It is a reasonable indication that the manufacturer intends to price this product tiered by dose. It is not a UK price.

How supply is likely to work in the UK

One relevant development: Eli Lilly launched LillyDirect in the UK on 25 June 2026. Despite the name, it is not direct-to-patient manufacturer supply — UK law does not permit that. It is a service through which private UK healthcare providers issue prescriptions that are then dispensed and delivered by Lilly’s dispensing partners.

At launch it covered tirzepatide only. Whether orforglipron will be added has not been confirmed by Lilly. If it is, that would be one route to UK patients alongside conventional wholesale supply to pharmacies — but this is not yet established, and we are not going to present it as though it were.

Buying it now: don’t

Orforglipron has not launched in the UK. There is no legitimate supply here.

Anyone currently offering to sell it, or to import it from the United States, is operating outside UK law. Medicines obtained that way sit entirely outside UK safety regulation: there is no assurance of what they contain, how they were stored, or whether they are the product at all. The MHRA has repeatedly seized unlicensed weight-loss medicines from the illegal market. In its largest such operation to date, around 12,000 doses were recovered from an illicit manufacturing site in England in May 2026, with two arrests.

The same applies, with knobs on, to “orforglipron” offered by websites that do not require a prescription. It is a prescription-only medicine. Any site willing to supply it without one is by definition not operating lawfully, whatever else it is willing to tell you.

What we will update, and when

• Within seven days: the UK Summary of Product Characteristics and patient information leaflet are due on the MHRA products website.
• Unknown date: Eli Lilly’s UK launch announcement and pricing.
• 18 November 2026: NICE guidance on the overweight and obesity indication is expected.

We will record the date of every change to this page at the foot of it.